Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Sharell Cornett-Risher
Phone: 713.441.3250
This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic a ... Read more >
Status: Open Not Enrolling
Investigator: Monisha Singh
Study Coordinator: Ashley Towne
Phone: 346.238.2006
This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The patient population durin ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Ashley Towne
Phone: 346.238.2006
Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >
Status: Open Not Enrolling
Investigator: Lisa Kopas
Study Coordinator: Elmira Ramos
Phone: 713.441.3248
The purpose of this research is to study a medical device that is designed to produce lung volume reduction. This device is called the PulmonX Endobronchial Valve (EBV). It has not been approved by the Food and Drug Administration (FDA) and is c ... Read more >
Status: Open Not Enrolling
Investigator: Lisa Kopas
Study Coordinator: Elmira Ramos
Phone: 713.441.3248
This registry is a post market observational, prospective, multi-center registry. It is designed to evaluate patient experience with the RePneu™ device for the relief of the emphysema symptoms and the continued collection of safety and effective ... Read more >
Status: Open Not Enrolling
Investigator: Swaminathan Iyer
Study Coordinator: Sharell Cornett-Risher
Phone: 713.441.3250
This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 monotherapy and R-907 (rituximab in combination with CUDC-907) in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Dif ... Read more >
Status: Enrolling
Investigator: Ahmed Gaber
Study Coordinator: Darrel Cleere
Phone: 713.441.6232
Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. This prolonged cour ... Read more >
